BIOLIFE4D

11 articles about BIOLIFE4D

• BIOLIFE4D Announces Intention to Submit Draft Registration Statement for Underwritten Public Offering of Common Stock

  12/31/2021

  BIOLIFE4D Corporation today announced that it intends to submit a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission in early 2022 for a proposed underwritten public offering of its common stock.

• BIOLIFE4D Names Pharmaceutical Veteran Kate Lewis as PresidentCompany’s first female executive to lead commercialization efforts of BIOLIFE4D’s live-saving 3D bioprinting technologies

  9/21/2020

  BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has named Kate Lewis as President of the company.

• BIOLIFE4D CSO Dr. Ravi Birla Publishes Paper in Prestigious APL Bioengineering Scholarly JournalBirla co-published paper with Stuart K. Williams, a renowned industry figure, to highlight 3D bioprinting’s impact on cardiac failure treatment

  2/27/2020

  BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, announced its Chief Science Officer, Dr. Ravi Birla, has published a paper in the prestigious APL Bioengineering scholarly journal.

• 

  BIOLIFE4D Successfully 3D Bioprints a Miniature Human Heart—One Step Closer to Bioprinting Transp...

  9/16/2019

  The miniature heart had all the structures of a full-sized heart, with four internal chambers. The company says it is as close as anyone has gotten to a fully functioning heart via 3D bioprinting.

• BIOLIFE4D Signs Laboratory Service Agreement With Northwestern University

  2/5/2018

  Agreement provides access to world class academic research facilities and resources, including sophisticated imaging and instrumentation capabilities,.

• BIOLIFE4D Targets High Growth Healthcare 3D Printing Market as it Readies for Regulation A+ Offering

  1/17/2018

  Healthcare 3D printing market projected to reach $2.2B by 2024, driven by applications in tissue engineering and regenerative medicine; Company prepares to take investments for its pioneering 3D bioprinting technology.

• BIOLIFE4D Names Dr. Ravi Birla as Its Chief Science Officer

  1/2/2018

  Company adds renowned stem cell expert from the Texas Heart Institute to lead research as it continues development of its lifesaving heart transplant technology.

• BIOLIFE4D Proceeding on Mission to Bioprint Human Hearts, Taps Regenerative Biomaterials Expert Adam W. Feinberg, Ph.D. to Lead Scientific Advisory Team

  11/13/2017

  BIOLIFE4D seeks to optimize a process that will capitalize on the growing number of milestones that have been reached in the field of 3D bioprinting recently.

• BIOLIFE4D Appoints Texas Heart Institute Surgeon Dr. Jeffrey Morgan Chief Medical Officer, Bolstering Leadership Team

  10/16/2017

  Bioprinting startup BIOLIFE4D named accomplished thoracic and cardiac surgeon Jeffrey Morgan M.D., FACS, FACC as CMO.

• BIOLIFE4D Welcomes Computational Medicine And Biomedical Engineering Expert Raimond Winslow, Ph.D. To Scientific Advisory Team

  10/13/2017

• Biotech Pioneer BIOLIFE4D Submits Regulation A+ Filing With SEC For Up To $50 Million Initial Public Offering

  9/7/2017